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Background: Administration of HMG-CoA reductase inhibitors (statins), prior to ischemia or prior to reperfusion has
been shown to decrease ischemia-reperfusion renal injury in animal studies. It is unknown whether this protective
effect is applicable to renal transplantation in humans. The aim of this study was to determine the relationship
between prior statin use in renal transplant recipients and the subsequent risk of delayed graft function.
Methods: All patients who underwent deceased or living donor renal transplantation at the Princess Alexandra
Hospital between 1 July 2008 and 1 August 2010 were included in this retrospective, observational cohort study.
Graft function was classified as immediate graft function (IGF), dialysis-requiring (D-DGF) and non-dialysis-requiring
(ND-DGF) delayed graft function. The independent predictors of graft function were evaluated by multivariable
logistic regression, adjusting for donor characteristics, recipient characteristics, HLA mismatch and ischaemic times.
Results: Overall, of the 266 renal transplant recipients, 21% exhibited D-DGF, 39% had ND-DGF and 40% had IGF.
Statin use prior to renal transplantation was not significantly associated with the risk of D-DGF (adjusted odds ratio
[OR] 1.05, 95% CI 0.96 – 1.15, P = 0.28). This finding was not altered when D-DGF and ND-DGF were pooled
together (OR 0.98; 95% CI 0.89-1.06, p = 0.56).
Conclusions: The present study did not show a significant, independent association between prior statin use in
kidney transplant recipients and the occurrence of delayed graft function.Background
Delayed graft function (DGF), describing impairment of
graft function immediately after transplantation, is asso-
ciated with significant morbidity, including increased risks
of acute allograft rejection, prolonged hospitalization,
higher health care costs and poorer graft survival [1-6].
The incidence of DGF in the renal transplant population
varies from as low as 4.7% in live related transplants [7] to
as high as 53-69% in kidneys following donation after car-
diac death (DCD) [8]. Factors associated with an increased
risk of DGF include both recipient factors (male gender,
pre-transplant diabetes mellitus, increased BMI, greater
HLA mismatch, higher panel reactive antibodies, previous
blood transfusions, previous transplants, pre-transplant* Correspondence: David_Johnson@health.qld.gov.au
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reproduction in any medium, provided the ordialysis) and donor factors (older age, anoxia, cerebrovas-
cular accident, hypertension, deceased donor, donation
after cardiac death [DCD], longer cold ischemic time and
higher terminal serum creatinine concentration) [9-12].
DGF is strongly associated with longer periods of ische-
mia between retrieval of the kidney from the donor and
subsequent reperfusion of the kidney in the recipient. Such
ischemic injury tends to be more marked in deceased
donor renal transplantation, particularly donation after
cardiac death [8]. The reintroduction of renal blood flow is
associated with the production of oxygen free radicals,
which in turn promote inflammation, necrosis, and apop-
tosis within the renal allograft [13,14]. Although there are
currently no treatments that effectively reduce the severity
of ischemia-reperfusion injury and delayed graft function,
3-hydroxymethylglutaryl coenzyme A inhibitors (also
known as statins) show considerable promise. In addition
to lowering serum cholesterol, these agents decrease the
formation of reactive oxygen species and inflammatoryLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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signal molecules (Ras, Rac1, cdc42 and Rho), so-called
pleiotropic effects [15]. Administration of statins prior to
ischemia or prior to reperfusion has been shown to de-
crease ischemia-reperfusion renal injury in rats [16-22].
However, it is unknown whether this protective effect is
applicable to renal transplantation in human beings.
The aim of this study was to determine the relation-
ship between prior statin use in renal transplant recipi-
ents and the subsequent risk of DGF.
Methods
All patients who underwent deceased or living donor
renal transplantation at the Princess Alexandra Hospital
between 1 July 2008 and 1 August 2010 were included in
this retrospective, observational cohort study. All T cell
cross matches were negative. The preservation fluid used
was University of Wisconsin preservation solution. An
interleukin-2 receptor antagonist (basiliximab) was rou-
tinely administered at induction of immunosuppression.
The immunosuppression regimen included a calcineurin
inhibitor (primarily tacrolimus), prednisolone and myco-
phenolate mofetil. Tacrolimus dosages were titrated to
maintain trough serum concentrations between 8 and
10 μg/L. Cyclosporine was used in a small minority of
patients with a low immunological risk or if there was a
contra-indication for tacrolimus use. All anti-hypertensive
agents were ceased prior to transplantation and avoided
during the first two post-operative weeks. Dopamine and
other inotropic agents were not administered to any re-
cipient during the study period.
Data collection
Data collection for the study was approved by the Prin-
cess Alexandra Hospital Research Ethics Committee and
individual consent was obtained from all transplant reci-
pients. For each patient, demographic data, operative
data, donor data, post-operative complications, medical
complications, admission histories, medications and
renal allograft function were prospectively recorded on a
computerised integrated renal database. If recipients
were using statins prior to transplantation, the type and
dose of statin were recorded. Unfortunately there were
no data available concerning the duration of statin use
prior to transplantation.
Classification and outcome measure
Graft function after transplantation was classified as
dialysis- delayed graft function (D-DGF) when recipients
required dialysis within the first 72 h post transplant-
ation, non-dialysis delayed graft function (ND-DGF)
[23,24] when the creatinine reduction ratio at post-
operative day 2 (CRR2) was less than 30% without the
need for dialysis and immediate graft function (IGF)when the CRR2 value was greater than 30%. The CRR2
was calculated using the creatinine levels on post opera-
tive days 1 (Cr1) and 2 (Cr2) using the following formula:
CRR2 %ð Þ ¼ Cr1 Cr2½   100ð Þ=Cr1
The primary outcome measure was the incidence of
delayed graft function ( both D-DGF and ND-DGF were
assessed).
Statistical analysis
Results are presented as number (%) for categorical data,
mean ± SD for continuous data and median (interquar-
tile range; 25th-75th percentile) for continuous variables
not normally distributed. Comparisons between groups
were made by χ2 test for categorical variables, unpaired
t-test for continuous normally distributed variables and
Mann–Whitney test for continuous variables not nor-
mally distributed. The independent predictors of DGF
were evaluated by multivariable logistic regression using
backward stepwise elimination based on a p value cut-
point of 0.2 until the most parsimonious model was
identified. Variables initially included in the model were
donor characteristics (age, gender, body mass index
[BMI], hypertension, diabetes mellitus, smoking status,
donor type, cause of death, inotropic support, estimated
glomerular filtration rate [eGFR]), recipient characteris-
tics (age, gender, race, BMI, hypertension, cardiovascular
disease, diabetes mellitus, smoking status, end-stage
renal failure cause, prior renal replacement therapy, pre-
vious renal transplantation) and operation characteristics
(number of HLA mismatches, cold ischemic time, warm
ischemic time). BMI was categorized as underweight
(<18.5 kg/m2), normal range (18.5-24.99 kg/m2), over-
weight (25–29.99 kg/m2) and obese (>30 kg/m2) accord-
ing to the World Health Organization [25].
First-order interaction terms between the significant
covariates were examined for all models. Data were ana-
lysed using the software packages SPSS for Windows,
Release Version 18.0, (© SPSS, Inc., 2009, Chicago, IL,
www.spss.com). P values less than 0.05 were considered
statistically significant. No assumptions were made
regarding missing data and all proportions were calcu-
lated as percentages of the patients with available data.
Results
Population characteristics
A total of 270 patients underwent renal transplantation
during the study period. 269 patients were included in
the final analysis as prior statin use could not be deter-
mined in one recipient. Of these, 93 (35%) patients were
using statins prior to transplantation. Compared with
patients not receiving statins, prior statin users were sig-
nificantly more likely to be older, hypertensive and a
Table 1 Baseline recipient, donor and transplant procedure characteristics
Characteristics Statin Non-statin Total p-value
N=93 N=176 N=269
Recipient characteristics
Age (years) 53.7 ± 11.0 47.5 ± 13.5 49.7 ± 13.0 <0.001
Male gender (%) 62(67%) 115(65%) 177(66%) 0.83
Race 0.06
Caucasian 81(87%) 150(85%) 231(86%)
Other 12(13%) 26(15%) 38(14%)
Body Mass Index1 (kg/m2) 0.08
<18,5 1(1%) 5(3%) 6(2%)
18.5-24.9 33(37%) 76(43%) 109(41%)
25-29.9 32(35%) 70(40%) 102(38%)
>30 24(27%) 25(14%) 49(19%)
Co-morbidities
Hypertension 89(96%) 148(84%) 237(88%) 0.005
Coronary artery disease 11(12%) 12(7%) 23(9%) 0.16
Peripheral vascular disease 4(4%) 5(3%) 9(3%) 0.53
Cerebrovascular disease 2(2%) 2(1%) 4(1%) 0.51
Chronic lung disease 6(7%) 12(7%) 18(7%) 0.91
Diabetes mellitus 9(10%) 12(7%) 21(8%) 0.41
Smoker 0.78
Current 1(1%) 1(1%) 2(1%)
Former 41(44%) 84(48%) 125(46%)
Never 51(55%) 91(51%) 142(53%)
Etiology of ESRD 0.18
Polycystic kidney disease 23(25%) 30(17%) 53(19%)
Glomerulonephritis 14(15%) 33(19%) 47(17%)
Focal sclerosing 4(4%) 6(3%) 10(4%)
Focal and segmental proliferative 0(0%) 9(5%) 9(3%)
IgA nephropathy 14(15%) 29(16%) 43(16%)
Reflux nephropathy 8(9%) 19(11%) 27(10%)
Diabetic nephropathy 7 (8%) 4 (2%) 11 (4%)
Other 27(29%) 61(35%) 88(33%)
Renal replacement therapy 0.55
Haemodialysis 56(60%) 97(55%) 153(57%)
Peritoneal dialysis 27(29%) 52(30%) 79(29%)
None 10(11%) 27(15%) 37(14%)
Previous transplants 15% 9% 11% 0.10
Length of admission (days) 8.6 ± 4.2 7.9 ± 3.8 8.2 ± 4.0 0.19
Donor characteristics
Age at transplant (years) 47.8 ± 14.6 44.0 ± 15.2 45.33 ± 13.02 0.05
Male gender (%) 42(45%) 83(47%) 125(47%) 0.76
Body Mass Index1 (kg/m2) 0.23
<18.5 0(0%) 8(5%) 8(3%)
18.5-24.9 32(35%) 57(33%) 89(34%)
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Table 1 Baseline recipient, donor and transplant procedure characteristics (Continued)
25-29.9 42(46%) 76(43%) 108(45%)
>30 17(19%) 32(19%) 49(18%)
Co-morbidities
Hypertension 14(15%) 20(11%) 34(13%) 0.38
Hypertension 14(15%) 20(11%) 34(13%) 0.38
Diabetes 2(2%) 4(2%) 6(2%) 0.83
Current 23(25%) 49(28%) 72(27%)
Former 21(22%) 36(20%) 56(21%)
Never 49(53%) 91(52%) 140(52%)
Donor type 0.35
Donation after brain death 49(53%) 94(53%) 143(53%)
Donation after cardiac death 13(14%) 15(9%) 28(10%)
Life 31(33%) 67(38%) 98(37%)
Cause of death 0.36
Subarachnoid haemorrhage 22(36%) 28(26%) 50(29%)
Cardiac arrest 6(10%) 19(17%) 25(15%)
Intracranial haemorrhage 9(14%) 15(14%) 24(14%)
Cyclist 6(10%) 4(4%) 10(6%)
Fall 4(6%) 5(4%) 9(5%)
Traffic accident 2(3%) 5(4%) 7(4%)
Hypoxia 3(5%) 4(4%) 7(4%)
Other 10(16%) 29(27%) 39(23%)
Inotropic support 52(84%) 95(87%) 147(86%) 0.55
eGFR (mL/min/1.73 m2) 90.8 ± 22.8 94.4 ± 25.0 93.2 ± 24.3 0.25
Transplant procedure characteristics
Mismatch 3(2–5) 4(2–5) 4(2–5) 0.05
Cold ischaemic time (hours) 8.2 ± 4.5 7.6 ± 4.5 7.7 ± 4.5 0.29
Warm ischaemic time (hours) 0.6 ± 0.2 0.6 ± 0.2 0.6 ± 0.2 0.93
1BMI classification according to the WHO.
Reiling et al. BMC Nephrology 2012, 13:111 Page 4 of 9
http://www.biomedcentral.com/1471-2369/13/111lower degree of HLA mismatch with the donor. They
also tended to have a higher BMI, a history or prior
renal transplantation and a kidney from an older donor
(Table 1). There were no statistically significant differ-
ences between the two groups with respect to presence
of cardiovascular disease, diabetes mellitus or any of the
other donor, recipient or operative characteristics listed
in Table 1.
The majority (77%) of recipients using statins prior to
transplantation were prescribed atorvastatin followed by
simvastatin (14%), pravastatin (8%) and rosuvastatin
(1%). 97% of the atorvastatin users used a daily dose of
40 mg or less (Table 2).
Graft function after transplantation
Table 3 shows graft function after transplantation. The
CRR2 of 3 patients could not be calculated and were
therefore excluded from the analysis. Overall, 57 (21%)of renal transplant recipients exhibited D-DGF, 103
(39%) exhibited ND-DGF and 106 (40%) exhibited IGF.
The occurrence of D-DGF was comparable between
recipients who did and did not use statins prior to
renal transplantation (21 (23%) versus 36 (21%), re-
spectively, p = 0.69). The occurrence of ND-DGF was
not significantly different between statin users and
non-statin users (40 (43%) versus 63(36%), p = 0.25).
When we pooled D-DGF and ND-DGF, the overall
rate of DGF was not significantly different between
statin users and non-statin users (61 (66%) versus 99
(57%), respectively, p = 0.14). The rates of pooled D-DGF
and ND-DGF were comparable between patients using
atorvastatin and those using other statins (38 (66%) versus
23(68%), respectively, p = 0.32).
The rates of acute rejection were not significantly dif-
ferent between recipients using statins (n = 16, 17%) and
those who did not (n = 17, 10%; p = 0.17).
Table 2 Types of statins used in recipients
Statin type Frequency (N = 93) Percentage of total
Atorvastatin
10 mg 21 22.6%
20 mg 29 31.2%
40 mg 20 21.5%
80 mg 2 2.2%
Total 72 77.4%
Pravastatin
20 mg 3 3.2%
40 mg 4 4.3%
Total 7 7.5%
Simvastatin
5 mg 1 1.1%
10 mg 3 3.2%
20 mg 8 8.6%
40 mg 1 1.1%
Total 13 14.0%
Rosuvastatin
40 mg 1 1.1%
Total 1 1.1%
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Using multivariable logistic regression analysis, D-DGF
was not significantly associated with statin use (adjusted
odds ratio [OR] 1.05, 95% CI 0.96 – 1.15 p = 0.28)Table 3 Graft function after transplantation


















IGF, Immediate Graft Function; ND-DGF, Non Dialysis dependent Delayed Graft func(Table 4). Clustered D-DGF+ND-DGF was also not sig-
nificantly associated with statin usage (OR 0.98; 95% CI
0.89-1.06, p = 0.56) (Table 5). Older age and BMI greater
than 30 kg/m2 were significantly associated with a higher
likelihood of D-DGF+ND-DGF, whilst undergoing live
donor kidney transplantation was associated with a
lower likelihood of D-DGF+ND-DGF.
Sensitivity analyses were performed with stratification
by donor type. These demonstrated that statin use in liv-
ing donor transplants was not significantly associated
with D-DGF (p = 0.99) or clustered D-DGF+ND-DGF
(OR 0.88 95% CI0.76 - 1.01; p = _0.06). Similarly, statin
use in donation after brain death (DBD) transplants was
not significantly associated with D-DGF (OR 1.04; 95%
CI0.91 -1.18; p = 0.58) or clustered D-DGF+ND-DGF
(OR 1.06; 95% CI 0.94 -1.19; p = 0.33). Multivariable lo-
gistic regression analyses were not able to be performed
for the small number of kidneys donated after cardiac
death (Table 1).
Discussion
The present study is the first to examine the relationship
between statin use and the occurrence of delayed graft
function (DGF) following renal transplantation in humans.
The key finding was that statin use by recipients prior to
renal transplantation was not observed to be significantly
associated with the risk of D-DGF. This finding was not
altered when D-DGF and ND-DGF were pooled together.
These findings contrast with previous studies in rat
models of ischemia-reperfusion injury whereby statinn Non-statin Total p-value
2 N=174 N=266
0.32
%) 75(43%) 106(40%) 0.14
%) 63(36%) 103(39%) 0.25
%) 36(21%) 57(21%) 0.69












tion; D-DGF, Dialysis dependent Delayed Graft Function.
Table 4 Results of multivariable logistic regression
analysis of predictors of delayed graft function requiring
















Donation after brain death 10.37 3.75-28.66 <0.01
Transplant procedure characteristics
Warm Ischemic Time (hours) 24.37 2.98-199.29 0.03
Only statin use and statistically significant variables in the final adjusted
regression model are shown.
* The final variables included in the model were donor characteristics
(hypertension, diabetes mellitus, smoking status, donor type, cause of death,
inotropic support, estimated glomerular filtration rate [eGFR]), recipient
characteristics (gender, race, BMI, diabetes mellitus, smoking status, end-stage
renal failure cause, previous renal transplantation, use of statins) and operation
characteristics (cold ischemic time, warm ischemic time).
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verity of acute kidney injury [16-18,21]. Statins have also
have been found to protect against experimental ische-
mic injury to gut [19], liver [20] and lung [20] tissue. The
apparent disparity in findings between these studies and
ours may be potentially explained by the appreciably
higher doses of statins administered in the animal models
(1–10 mg/kg) and the modifying influences of immuno-
suppressive agents in human renal transplantation, which
were not examined in the animal models. However, a
previous study by our group demonstrating a significant
renoprotective effect of simvastatin on cyclosporine-Table 5 Results of multivariable logistic regression
analysis of delayed graft function (DGF=D-DGF+
ND-DGF) N=256*
Characteristics Odds ratio Confidence interval P value
Recipient characteristics
Body Mass Index (kg/m2)
>30 versus 18.5-24.99 6.14 2.27-16.57 <0.01
<18.5 versus 18.5-24.99 1.24 0.14-11.22 0.85
25-29.99 versus 18.5-24.99 2.03 1.00-4.13 0.05
Statin use (yes versus no) 0.98 0.39-1.06 0.59
Only statin use and statistically significant variables in the final adjusted
regression model are shown.
* The initial variables included in the model were donor characteristics (body
mass index [BMI], hypertension, smoking status, donor type, cause of death,
inotropic support) recipient characteristics (age, , BMI, hypertension, diabetes
mellitus, smoking status, end-stage renal failure cause, prior renal replacement
therapy, use of statins) and operation characteristics (cold ischemic time).induced injury in primary cultures of human proximal
tubule cells argues against abrogation of the renoprotec-
tive effect of statins by calcineurin inhibitors in
transplantation-related ischaemia-reperfusion injury [26].
Furthermore, the beneficial effects of statins on human
proximal tubule cell injury were independent of the
mevalonate-cholesterol pathway [26].
Another reason for the disparity in findings may be
the use of animal models for ischemia reperfusion injury.
Cardinal differences between animal models and patients
exist that may contribute to the differences in study out-
comes [27,28]. In animal studies, statins were mostly
administered through intraperitoneal and intravenous
injection whereas the oral route is typically used in
humans. Furthermore, in all previous studies of rat
models of ischemia-reperfusion injury, the kidney was
pre-treated with statins prior to ischemia or prior to
reperfusion. Statin use in the donor population was not
recorded in this study. We believe it would be uncom-
mon for the donor population to be coincidentally re-
ceiving statin administration. Statin use prior to hospital
admission has been reported in up to 30% of the inten-
sive care patients [29-31]. It is unlikely that this number
is representative of the donor population given their
lower age and minor comorbidities [32]. Even for those
donor patients that may have been on prior statin ther-
apy, it is common practice to discontinue statins in crit-
ically ill patients because of concern regarding serious
side effects [29,33]. Administration of statins to donors
prior to organ retrieval (and onset of ischemic acute kid-
ney injury) was not assessed in this study and would re-
quire separate evaluation. Indeed, early inflammatory
and stress responses can be detected in donor kidneys
prior to their retrieval from brain dead patients [34].
It is also possible that prior statin treatment of renal
transplant recipients needed to be continued into the
early post-operative period to realize any potential bene-
ficial effects on DGF. In the present study, statin users
had their statins temporarily interrupted in the immedi-
ate post-transplant period until reliable oral intake was
re-established, usually around post operative day 2. The
literature is divided on the risks or benefits of cessation
of maintenance statin therapy in hospitalised patients. It
has been shown in previous investigations that cessation
of statins in certain clinical settings, such as after coron-
ary syndromes [35], acute stroke [36] and major non-
cardiac surgery [37], is associated with significantly
increased morbidity and mortality. However, these find-
ings were refuted by a recent randomized controlled trial
in which the cessation of statins in patients with pre-
sumed infection was not associated with an inflammatory
rebound effect or other adverse clinical consequences
[31]. Given the higher incidence of ND-DGF in prior sta-
tin users (40 (43%) versus 63 (36%) P= 0.25), we consider
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this patient population is warranted.
The present study cannot exclude the possibility that
some statins may be more effective in mitigating DGF
than others. Atorvastatin was used in the majority (77%)
of recipients in our study, reflecting common practice in
Australia [38]. Atorvastatin, simvastatin, pravastatin and
rosuvastatin all have different pharmacokinetics, includ-
ing half-life time, lipophilicity and potency [39]. Al-
though pleiotrophic effects of statins are generally
considered to represent a class effect [15], most studies
have shown a protective effect of statins in ischemia-
reperfusion injury with simvastastin [16-18,21], whilst
only one study used atorvastatin [40]. A previously pub-
lished systematic review by our group of 5 randomised
controlled trials found no significant effect of statin use
on the risk of acute rejection in renal transplant recipi-
ents (relative risk 0.61, 95% CI 0.32-1.16) [41]. Data were
not available to evaluate the effect of statins on DGF.
One of the challenges of the present study related to
the definition of DGF. There are at least 18 unique defi-
nitions of DGF employed in the literature [24]. The one
that is used most frequently is the need for dialysis post-
transplantation, although the specified timeframe in
which dialysis occurs is variable. The need for dialysis
within 72 hours after transplantation is the definition
used by the Australian and New Zealand Dialysis and
Transplant Registry (ANZDATA; www.anzdata.org.au)
and was therefore employed in this study. However,
given that such a conservative definition potentially
excludes a significant number of patients with less severe
forms of DGF, a sensitivity analysis was performed to in-
clude these patients using a broader definition. Govani
et al. devised and validated the creatinine reduction ratio
at post-operative day 2 (CRR2) <30% as a simple, object-
ive criterion for early diagnosis of DGF [23]. Both
Rodrigo et al. and Vilar et al. subsequently demonstrated
that patients with a CRR2 < 30% (ND-DGF) had a signifi-
cantly lower 5 year graft survival than patients with IGF
[3,4]. Nevertheless, regardless of whether the need for
dialysis post-renal transplantation was considered alone
or in combination with the CRR2 criterion, statin ther-
apy was not associated with DGF in the present study.
Our study has the expected limitations of a retrospective
study. Even though we adjusted for a number of patient
characteristics, the possibility of residual confounding
could not be excluded. Statin use in recipients was not
randomized and, as such, the results could be confounded
by indication bias. Statin users were significantly older
with more hypertensive disease and tended to have a
higher BMI, a history of prior renal transplantation and a
kidney from an older donor. Such characteristics are asso-
ciated with a higher incidence of DGF and could have
masked any potential beneficial renoprotective effect ofstatins. Pre-transplant anti-hypertensive medications in
both the donors and recipients were not recorded, such
that a differential pre-conditioning effect of these agents
on subsequent ischaemia-reperfusion injury in the statin
and non-statin users could not be excluded. Since statins
were only administered to recipients, the current result
might only reflect an effect in the reperfusion mediated
kidney injuries. Some important variables, such as recipi-
ent panel reactive antibodies, were not recorded. This was
a single centre study and thus the results may not be
generalisable.Conclusions
In conclusion, the present study did not show evidence
of a significant, independent association between the use
of statins in kidney transplant recipients and the occur-
rence of delayed graft function. Further studies on
delayed graft function should examine the effects of sta-
tin pretreatment of donors (with or without recipient
treatment) and the impact of continuing prior statin
therapy in recipients in the immediate post-operative
period.
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